Apollo invests in vVARDIS to expand Curodont product line
Swiss dental manufacturer vVARDIS secures Apollo funding to expand Curodont globally.
Swiss dental manufacturer vVARDIS has secured a strategic minority investment from Apollo, a global alternative asset management firm. The funding will support the company's next phase of global growth and commercial expansion, with a focus on rolling out its Curodont product line to new markets.
What Curodont offers
Curodont is vVARDIS's product line designed to address dental treatment needs across multiple segments. The investment signals Apollo's confidence in the technology's market potential and vVARDIS's ability to scale operations internationally.
Next steps for vVARDIS
The capital injection will accelerate the company's expansion strategy. vVARDIS plans to deepen its presence in existing markets while entering new regions. The partnership with Apollo, which manages alternative assets globally, provides both financial resources and operational expertise to support this growth trajectory.
Frequently asked questions
What is Curodont and what does vVARDIS do?
vVARDIS is a Swiss dental manufacturer producing the Curodont product line, which addresses dental treatment needs across multiple segments. The company is now scaling its commercial operations globally.
Why did Apollo invest in vVARDIS?
Apollo, a global alternative asset management firm, made a strategic minority investment to support vVARDIS's next phase of growth and expansion of its Curodont product line to new markets.
What will the Apollo funding be used for?
The investment will support global growth and commercial expansion, including continued rollout of Curodont to existing and new regions.
Is Apollo a new investor in vVARDIS?
Yes, Apollo has announced a strategic minority investment in vVARDIS, signalling the firm's confidence in the company's technology and ability to scale internationally.
